Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Director departure
Appointed director
Quarterly results
Consulting agrmnt
Employment agrmnt
Asset disposition
REPROS THERAPEUTICS INC. (RPRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/31/2018 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of Repros Therapeutic, Inc.",
"Amended and Restated Bylaws of Repros Therapeutic, Inc."
01/26/2018 8-K Other Events
Docs: "Repros Announces Negative Opinion From the EMA for Enclomiphene"
12/15/2017 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
12/15/2017 8-K Other Events
Docs: "Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency"
12/12/2017 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Allergan Sales, LLC, Celestial Merger Sub, Inc. and Repros Therapeutics Inc",
"Agreement for Amendment to Series A and Series B Warrants, by and between the Company and Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B",
"Agreement for Amendment to Series A and Series B Warrants, by and between the Company and Hudson Bay Master Fund Ltd",
"Agreement for Amendment to Series A and Series B Warrants, by and between the Company and KBB Asset Management",
"Agreement for Amendment to Series A and Series B Warrants, by and between the Company and Warberg Warrant Fund V",
"Form of Escrow Agreement, by and among Allergan Sales, LLC, the Company and JPMorgan Chase Bank, N.A",
"Repros Therapeutics Inc.® Announces Acquisition by Allergan plc"
11/13/2017 8-K Quarterly results
Docs: "Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results"
11/13/2017 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
10/13/2017 8-K Quarterly results
09/15/2017 8-K Quarterly results
09/11/2017 8-K Quarterly results
08/14/2017 8-K Quarterly results
Docs: "Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results"
07/26/2017 8-K Form 8-K - Current report:
07/21/2017 8-K Other Events
07/17/2017 8-K Form 8-K - Current report:
06/16/2017 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
05/31/2017 8-K Form 8-K - Current report
05/22/2017 8-K Form 8-K - Current report
05/17/2017 8-K Form 8-K - Current report
05/09/2017 8-K Form 8-K - Current report
05/02/2017 8-K Form 8-K - Current report
04/17/2017 8-K Form 8-K - Current report
04/13/2017 8-K Form 8-K - Current report
04/10/2017 8-K Form 8-K - Current report
03/31/2017 8-K Form 8-K - Current report
02/02/2017 8-K Form 8-K - Current report
01/30/2017 8-K Form 8-K - Current report
12/19/2016 8-K Form 8-K - Current report
12/12/2016 8-K Form 8-K - Current report
12/06/2016 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism THE WOODLANDS, Texas, Dec. 06, 2016 -- Repros Therapeutics Inc.® participated in the industry presentation at the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting today. The panel provided the FDA with advice regarding a clinical and regulatory path to approval for products, such as enclomiphene, in subjects with obesity-related hypogonadism who wish to maintain spermatogenesis. The panel voted 16 to 5 that the achievement of testosterone improvement while maintaining evidence of spermatogenesis was not sufficient, in and of itself, to provide evidence of clinical benefit. At the meeting, numerous panel members suggested that an additional endpoint related to symptoms should be assessed..."
11/15/2016 8-K Form 8-K - Current report
11/14/2016 8-K Form 8-K - Current report
11/08/2016 8-K Quarterly results
Docs: "Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results"
10/05/2016 8-K Form 8-K - Current report
09/26/2016 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy